The Developing Educational Initiatives for Implementation and Therapy Management of B-cell Maturation Antigen (BCMA) Bi-Specific Antibodies (BsAbs) in Relapsed/Refractory Multiple Myeloma (RRMM) Competitive Grant Program supports healthcare professional education across the United States. Issued by Pfizer Independent Medical Education, this program seeks to increase healthcare professional understanding and competency in the use and management of BCMA BsAbs for the treatment of RRMM.

Eligibility Requirements

Applicant organizations must be based in the United States. Eligible applicant types include medical, dental, nursing, allied health, and pharmacy professional schools; healthcare institutions; professional organizations or medical societies; medical education companies; and other entities with a mission related to healthcare professional education or healthcare improvement. Only organizations are eligible to receive grants; individuals and independent medical practice groups are not eligible. Projects involving multiple departments or institutions must have a clear key role for the requesting organization. The project lead must be an employee or contractor of the requesting organization. For projects offering continuing education credit, the requesting organization must be accredited.

Educational Focus and Funding

Projects should be designed to increase healthcare professional competency in BCMA BsAbs for RRMM. Target audiences include hematologists, oncologists, oncology nurses, nurse practitioners, physician associates, pharmacists, and other healthcare professionals involved in the care of patients with RRMM.

Areas of interest for educational initiatives include the following:

• Sharing successful practice models for BCMA BsAb implementation, including outpatient step-up dosing and multidisciplinary coordination of care.
• Addressing educational gaps in the community oncology setting regarding therapy initiation and patient transition from academic to community settings.
• Education on the assessment and management of adverse events, such as CRS, ICANS, and infection.
• Understanding sequencing strategies in myeloma and equipping patients and care partners with necessary knowledge and resources.

Funding of up to $125,000 per individual project will be considered, with an anticipated total of two to three proposals funded. Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs. Grant funds may not be used to purchase therapeutic assets.

Application Process and Key Dates

Applications must be submitted by May 18, 2026, at 23:59 Eastern Standard Time. Applications submitted after this deadline will not be reviewed.

To apply, visit www.cybergrants.com/pfizer/knowledge and sign in. First-time users must create a password. The online application must be completed in full, with the project proposal uploaded in the General RFP Submission field. In the application, select "Yes" for the Competitive Grant question, "Oncology – Hematologic" as the Primary Area of Interest, and "2026 ONC US Community Oncology Support for Therapy Management in MM IME" as the Competitive Grant Program Name. The project proposal should include details on goals and objectives, assessment of need, target audience, project design and methods, innovation, evaluation and outcomes, dissemination plan, anticipated timeline, organization details, and budget narrative.

Key timeline dates are as follows:

• RFP Release Date: March 27, 2026
• Submission Deadline: May 18, 2026
• Anticipated Grant Award Notification: June 2026
• Anticipated Project Start Date: July/August 2026

Questions regarding this RFP should be directed in writing to the Grant Officer, Sue Lee, at sue.lee@pfizer.com with the subject line "2026 ONC US MM Community Support RFP". For technical difficulties with the online portal, refer to the "Technical Questions" link within the grant submission system.